|Articles|September 10, 2020
- Pharmaceutical Executive-09-01-2020
- Volume 40
- Issue 9
Pharmaceutical Executive, September 2020 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive September 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 5 years ago
Our Launch-Time Menuover 5 years ago
Drug Launch: Winning the Evidence Battleover 5 years ago
COVID Causes Pharma Marketers to Watch TVover 5 years ago
Succession Plan: Skyriziover 5 years ago
New Standards for First-to-Launch Playersover 5 years ago
(O)mega Opportunity: Vascepaover 5 years ago
Educational Mission: Oxbrytaover 5 years ago
First in Class: Spravatoover 5 years ago
One Time for Lifetime: Zolgensmaover 5 years ago
Biopharma Capital Markets Sizzle in 2020Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Your Phase III Clinical Protocol Is Your Initial Product Launch
2
Pharmaceutical Executive Daily: Public Citizen Sues The Trump Administration Over Undisclosed Drug Price Agreements
3
AstraZeneca Enters $4.7 Billion Collaboration Agreement with CSPC Pharmaceuticals
4
Taking Advantage of ‘Hidden Gem’ Talent Hubs
5
